BRIEF—Section head of MSKCC joining Lilly Oncology as VP

US pharma major Eli Lilly announced on Friday that Maura Dickler, a prestigious breast cancer researcher, will join Lilly Oncology as vice president of late phase development on May 7, 2018.

Dr Dickler is currently the section head, Endocrine Therapy Clinical Research Program at Memorial Sloan Kettering Cancer Center (MSKCC).

She concurrently serves as associate member, Breast Medicine Service, Department of Medicine, MSKCC and Associate Professor of Medicine, Weill Cornell Medical College, New York.

She will report to Levi Garraway, senior vice president, global Development and medical affairs of Lilly Oncology.

"Dr Dickler is an internationally recognized oncology leader with drug development expertise spanning a wide range of therapeutic modalities," said Garraway, adding: "Moreover, she is an exceptionally gifted clinician for whom patients are at the center of everything she does. We are thrilled to have Dr Dickler join us at Lilly."